H.C. Wainwright Sticks to Its Buy Rating for Flexion Therapeutics (FLXN)


H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Flexion Therapeutics (FLXN) today and set a price target of $25.00. The company’s shares closed last Wednesday at $7.53, close to its 52-week low of $6.71.

According to TipRanks.com, Trucchio ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.3% and a 30.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Arrowhead Pharmaceuticals, and Precision BioSciences.

Currently, the analyst consensus on Flexion Therapeutics is a Strong Buy with an average price target of $20.63, a 182.2% upside from current levels. In a report issued on April 28, Raymond James also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Flexion Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $26.31 million and GAAP net loss of $19.65 million. In comparison, last year the company earned revenue of $23.65 million and had a GAAP net loss of $33.52 million.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FLXN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts